Pressure from payors and newer high-priced assays have expanded the gap between independent labs and hospital outreach businesses.
During its annual strategic planning, the firm identified its expanding base of MDx instruments as an essential driver of increasing revenues.
The company has used RNA sequencing to discover its marker set but plans to transition the assay to a PCR platform before it seeks regulatory clearance.
Intelligent Fingerprinting Adding SARS-CoV-2 Saliva Test to Portfolio of Drug-Testing Assays
Premium
The company plans to launch its COVID-19 test in the early fall with CE marking and submit to the US Food and Drug Administration for Emergency Use Authorization.
Acquired by private equity investor Martis Capital last year, DCN completed two strategic acquisitions last month, and it is pursuing others.
The digital pathology firm is working to further develop its diagnostic capabilities and broaden its menu of algorithms for different diseases.